Optimisation of patient-reported outcome measurement for haematological cancer patients receiving novel immunotherapies: perspectives of multi-stakeholders - Takeaways - MDSpire

Optimisation of patient-reported outcome measurement for haematological cancer patients receiving novel immunotherapies: perspectives of multi-stakeholders

  • By

  • Eilidh M Duncan

  • Jhulia Salviano

  • Charalampia Kyriakou

  • Samantha Nier

  • Simone Oerlemans

  • Sam Salek

  • Kate Morgan

  • Katie Joyner

  • May 4, 2026

  • 0 min

Share

  • 1

    The project aimed to address challenges in implementing patient-reported outcome measures (PROMs) for hematological cancer patients receiving CAR-T and BsAbs therapies.

  • 2

    Focus groups and interviews revealed complexities in capturing treatment-related side effects and patient experiences due to the unique nature of CAR-T and BsAbs.

  • 3

    Current PROMs often fail to adequately reflect patients' experiences, with only 27% of CAR-T trials utilizing these measures to assess treatment toxicities.

  • 4

    New PROMs, like the MDASI-CAR, have been developed but are limited in availability and may not fully capture the nuances of patients' experiences.

  • 5

    Improving PROMs requires clearer guidance, systematic inclusion of patient-important domains, and ongoing data collection beyond clinical progression.

Original Source(s)

Optimisation of patient-reported outcome measurement for haematological cancer patients receiving novel immunotherapies: perspectives of multi-stakeholders

  • by Eilidh M Duncan, Jhulia Salviano, Charalampia Kyriakou, Samantha Nier, Simone Oerlemans, Sam Salek, Kate Morgan, Katie Joyner

  • May 4, 2026

Related Content

The clinical relevance of sole loss of chromosome Y in myeloid neoplasms

Infection risk associated with teclistamab in relapsed/refractory multiple myeloma: a systematic review and meta-analysis of clinical trial and real-world evidence

Unsupervised risk factor identification across cancer types and data modalities via explainable artificial intelligence